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ABSTRACT
The periosteal and endocortical surfaces of cortical bone dictate the geometry and overall mechanical properties of bone. Yet the cellular
and molecular mechanisms that regulate activity on these surfaces are far from being understood. Parathyroid hormone (PTH) has
profound effects in cortical bone, stimulating periosteal expansion and at the same time accelerating intracortical bone remodeling. We
report herein that transgenic mice expressing a constitutive active PTH receptor in osteocytes (DMP1-caPTHR1 mice) exhibit increased
cortical bone area and an elevated rate of periosteal and endocortical bone formation. In addition, DMP1-caPTHR1mice display amarked
increase in intracortical remodeling and cortical porosity. Crossing DMP1-caPTHR1 mice with mice lacking the Wnt coreceptor, LDL-
related receptor 5 (LRP5), or with mice overexpressing the Wnt antagonist Sost in osteocytes (DMP1-Sost mice) reduced or abolished,
respectively, the increased cortical bone area, periosteal bone formation rate, and expression of osteoblast markers andWnt target genes
exhibited by the DMP1-caPTHR1 mice. In addition, DMP1-caPTHR1 lacking LRP5 or double transgenic DMP1-caPTHR1;DMP1-Sost mice
exhibit exacerbated intracortical remodeling and increased osteoclast numbers, and markedly decreased expression of the RANK decoy
receptor osteoprotegerin. Thus, whereas Sost downregulation and the consequent Wnt activation is required for the stimulatory effect of
PTH receptor signaling on periosteal bone formation, the Wnt-independent increase in osteoclastogenesis induced by PTH receptor
activation in osteocytes overrides the effect on Sost. These findings demonstrate that PTH receptor signaling influences cortical bone
through actions on osteocytes and defines the role of Wnt signaling in PTH receptor action.  2011 American Society for Bone and
Mineral Research.
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Introduction
The skeleton is composed of cancellous or trabecular boneintertwined with bone marrow surrounded by a shell of
cortical bone. Bone formation on the periosteal surface of cortical
bone regulates the outer shape of bones and, in concert with
activity on the endocortical surface, determines cortical
thickness and bone size. Periosteal expansion significantly
increases bone strength, independently of increases in areal
bone mineral density.(1,2) Fractures in clinically relevant sites
initiate in the cortical bone,(3) even in bones composed
predominantly of cancellous bone such as the femoral neck.(4)
Moreover, greater cortical bone mass may explain the higher
resistance to vertebral fracture in males compared to females.(5,6)
Despite the influence of cortical bone and specifically the
periosteum on fracture prevention, the mechanisms that govern
cortical bone biology and the response of this site to
osteoporotic therapies are far from being understood.
Mechanical and hormonal stimuli influence periosteal bone
formation during growth as well as in the adult skeleton.(7) In
particular, parathyroid hormone (PTH) is a key stimulator of
periosteal expansion.(8) Early studies in humans showed that
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asymptomatic patients with either primary hyperparathyroidism
or hyperparathyroidism secondary to chronic kidney disease
exhibit increased metacarpal outer diameter.(8) Consistent with
this finding, patients with primary hyperparathyroidism exhibit
2- to 3-fold higher periosteal bone formation rate (BFR) than
controls do.(9) Daily injections of PTH to osteoporotic patients
also augment cortical bone width and increase BFR on both
periosteal and endocortical surfaces.(10) In rodents and rabbits,
intermittent PTH administration enhances periosteal bone
formation(11–14) by a mechanism that might require insulin-like
growth factor 1 signaling.(15,16) All this evidence notwithstand-
ing, elevation of PTH does not always increase bone formation
on the periosteal surface.(17–19) The bases for this apparent
dichotomy are not understood.
In cancellous bone, PTH increases bone formation by
mechanisms that seem to differ depending on the mode of
elevation. The anabolic effect of intermittent PTH in rodents can
be accounted for by prolonging the life span of mature
osteoblasts in combination with the pro-differentiating effects of
the hormone,(20–22) whereas chronic elevation of PTH increases
osteoblast number by acting on osteocytes to suppress the
expression of the bone formation inhibitor sclerostin, encoded
by the Sost gene.(23,24) Recent evidence shows that transgenic
mice expressing a constitutively active PTH receptor 1 exclusively
in osteocytes (DMP1-caPTHR1 mice) exhibit reduced sclerostin
expression, increased Wnt signaling, and increased cancellous
bone volume.(25) In addition, these mice display elevated bone
turnover markers. These findings suggest that previously
unrecognized effects of PTH on osteocytes mediate at least
some of the actions of the hormone on the skeleton. Whether
PTH regulates cortical bone by acting on osteocytes was
heretofore unknown.
We report here that osteocyte-specific constitutive activation
of the PTH receptor leads to increased cortical bone area and an
elevated rate of periosteal and endocortical bone formation. In
addition, DMP1-caPTHR1 mice display a remarkable increase in
intracortical remodeling associated with increased cortical
porosity. Removal of the Wnt coreceptor, LDL-related receptor
5 (LRP5), or osteocyte-targeted overexpression of Sost, whose
product sclerostin binds to both LRP5 and 6, reduced or
abolished, respectively, the increased cortical bone area,
periosteal BFR, and expression of osteoblast markers and Wnt
target genes exhibited by the DMP1-caPTHR1 mice. In addition,
interference with the Wnt pathway exacerbated intracortical
remodeling and the increase in osteoclast number displayed by
the DMP1-caPTHR1mice andmarkedly decreased the expression
of the RANK decoy receptor osteoprotegerin (OPG). These
findings show that PTH receptor signaling influences cortical
bone through actions on osteocytes and defines the role of Wnt
signaling in PTH receptor action.
Materials and Methods
Generation of DMP1-caPTHR1 and DMP-Sost transgenic
mice and crosses with LRP5/ mice or DMP1-Sost mice
Generation of DMP1-caPTHR1 transgenic mice has been
described previously.(25) DMP1-Sost transgenic mice were
generated by inserting the human Sost cDNA (I.M.A.G.E. clone
ID 40009482, American Tissue Culture Collection, Manassas, VA,
USA) downstream from a 12-kb DNA fragment containing 8 kb of
the 50-flanking region, the first exon, the first intron, and 17 bp of
exon 2 of themurine DMP1 gene(26) and upstream from a 140-bp
fragment containing the rabbit beta-globin polyadenylation
sequence. Transgenic mice were produced by microinjection of
purified DNA into pronuclei of C57BL/6 mice at the transgenic
mouse core facility of the University of Arkansas for Medical
Sciences. DMP1-Sost mice were born at the expected Mendelian
frequency, were fertile, and exhibited normal size and weight.
DMP1-caPTHR1 and DMP1-Sost mouse colonies were main-
tained by breeding mice hemizygous for the transgene with wild
type C57BL/6 mice. All transgenic mice used in these studies
were hemizygous. The DMP1-caPTHR1 and DMP1-Sost trans-
genes were detected in bone but not in skeletal muscle, heart,
brain, kidney, duodenum, or colon(25) (see also Supplemental
Fig. 1A, B).
DMP1-caPTHR1 mice were crossed with mice lacking LRP5(27)
or with DMP1-Sost mice to obtain mice expressing the DMP1-
caPTHR1 transgene in an LRP5-deficient background or mice
expressing both the DMP1-caPTHR1 and the DMP1-Sost
transgenes. Animals were fed a regular diet (Harlan/Teklad
7001, Indianapolis, IN, USA) and water ad libitum and were
maintained on a 12-hour light/dark cycle. Animal protocols were
approved by the Institutional Animal Care and Use Committees
of the University of Arkansas for Medical Sciences and the
Indiana University School of Medicine.
Analysis of skeletal phenotypes
Analysis of skeletal phenotypes was performed inmice of 4.6 and
12 weeks of age as indicated in the figure legends. Bone mineral
density (BMD) was determined by dual energy x-ray absorptio-
metry (DXA) using a PIXImus II densitometer (GE Medical
Systems, Madison, WI, USA) as previously described.(25) Mice
were anesthetized by inhalation of 2.5% isoflurane (Abbott
Laboratories, Abbott Park, IL, USA) mixed with O2 (1.5 liters/
minute). BMD measurements of the total body excluding the
head, lumbar spine, and femur were taken. For micro-CT analysis,
femora and L3 vertebra were dissected, cleaned of soft tissue,
stored in 70% ethanol, and scanned at 6-micron resolution
(Skyscan 1172, SkyScan, Kontich, Belgium). For histomorpho-
metric analysis, femora and calvariae were dissected, fixed, and
embedded inmethyl methacrylate. Fluorochrome labeling of the
bones was performed by intraperitoneal injections of calcein
(30mg/kg) and alizarin (50mg/kg; Sigma Chemical, St. Louis, MO,
USA) administered 7 and 2 days, respectively, before the mice
were killed, as previously described.(25) Thick cross-sections of
undecalcified femora at themid-diaphysis were prepared using a
diamond-embedded wire saw (Histosaw, Delaware Diamond
Knives, Wilmington, DE, USA) and ground to a final thickness of
30–35mm. Frontal-plane 8mm–thick calvarial sections were
obtained 2mm anterior to the junction between the frontopar-
ietal and sagittal sutures using an Automated Rotary Microtome
Leica RM2255 (Leica Microsystems, Bannockburn, IL, USA).
Sections were viewed at 20–40x magnification on a Leitz
DMRXE microscope (Leica Mikroskopie und System GmbH,
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Wetzlar, Germany). Images were captured using a SPOT digital
camera (Diagnostic Instruments, Sterling Heights, MI, USA).
Single- and double-labeled perimeter and interlabel width were
measured on the periosteal and endocortical surfaces of 2
femoral sections per mouse and on the outer and inner
periosteal surfaces of 1 calvarial section per mouse, using a
semiautomatic analysis system (Bioquant OSTEO 7.20.10,
Bioquant Image Analysis Co., Nashville, TN, USA) attached to a
microscope equipped with an ultraviolet light source (Optiphot 2
microscope, Nikon, Melville, NY, USA). Von Kossa was used to
stain mineralized bone, followed by enzyme histochemistry for
TRAPase and counterstain with Gill’s III hematoxylin for
visualizing osteoclasts in calvarial sections.(25,28) TRAPase-
positive multinucleated cells were counted using the Osteo-
Measure High Resolution Digital Video System (OsteoMetrics,
Decatur, GA, USA) attached to an Olympus BX51TRF microscope
(Olympus America, Center Valley, PA, USA). Osteoclast number
was expressed per bone area. The terminology and units used
are those recommended by the Histomorphometry Nomencla-
ture Committee of the American Society for Bone and Mineral
Research.(29)
Bone turnover markers
Plasma osteocalcin and C-telopeptide fragments of type I
collagen (CTX) were measured using enzyme-linked immuno-
sorbent assays (Biomedical Technologies, Stoughton, MA, USA,
and Immunodiagnostic Systems, Fountain Hill, AZ, USA,
respectively), as published.(25)
Immunohistochemistry
Detection of sclerostin expression on paraffin-embedded tibiae
from 6-week-oldmicewas performed as previously described.(24,25)
Briefly, sections were deparaffinized, treated with 3% H2O2 to
inhibit endogenous peroxidase activity, blocked with rabbit or
goat serum, and then incubated with a 1:100 dilution of goat
polyclonal antimouse sclerostin antibody (R&D Systems, Min-
neapolis, MN, USA) or rabbit polyclonal anti-human sclerostin
antibody (Abcam, Cambridge, MA, USA), respectively. Sections
were then incubated with rabbit anti-goat horseradish perox-
idase-conjugated secondary antibody (Santa Cruz Biotechnolo-
gies, Santa Cruz, CA, USA) or goat antirabbit biotinylated
secondary antibody followed by avidin-conjugated peroxidase
(Vectastain Elite ABC Kit; Vectora Laboratories, Burlingame, CA,
USA). Color was developed with a diaminobenzidine substrate
chromogen system (Dako, Carpinteria, CA, USA). Nonimmune
IgGs were used as negative controls.
Quantitative PCR
Whole tibiae from 12-week-old DMP1-caPTHR1;LRP5/ mice or
ulnae from 6-week-old DMP1-caPTHR1;DMP1-Sost mice were
snap frozen. Total RNA was purified using Ultraspec reagent
(Biotecx Laboratories, Houston, TX, USA) according to the
manufacturer’s instructions. Gene expression was analyzed by
quantitative PCR as previously described(25) using primer probe
sets from Applied Biosystems (Foster City, CA, USA) or from
Roche Applied Science (Indianapolis, IN, USA). Relative mRNA
expression levels were normalized to the housekeeping gene
ribosomal protein S2 using the DCt method.
Statistical analysis
Data were analyzed using SigmaStat (SPSS Science, Chicago, IL,
USA). All values are reported as the mean standard deviations
(SD). Differences between group means were evaluated using
Student’s t-test or two-way ANOVA.
Results
Mice expressing a constitutively active PTHR1 in
osteocytes exhibit increased cortical bone area and
elevated periosteal and endocortical bone formation
Microscopic examination of cross-sectional cuts of the femur at
mid-diaphysis of 4.6-week-old mice showed larger bone
diameter in DMP1-caPTHR1 bones (Fig. 1A). Histomorphometric
analysis showed that the total cross-sectional area was 17% higher
and cortical thickness and cortical bone area approximately double
in the DMP1-caPTHR1 mice (Fig. 1B). These geometry differences
resulted from enhanced activity on both cortical surfaces. Also,
whereas wild type (WT) littermate midshafts exhibited the classical
pattern of modeling with fluorochrome labeling present only in
part of the periosteal and the opposite endocortical surfaces,
fluorochrome incorporation in DMP1-caPTHR1 bones was
observed along the entire periosteal and endocortical surface
(Fig. 1A). Mineralizing surface per bone surface (MS/BS) was
markedly increased in the periosteal and endocortical surface of
DMP1-caPTHR1 mid-diaphyses relative to those of WT littermates.
Mineral apposition rate (MAR) was also increased in both periosteal
and endocortical surfaces, although the effect was statistically
significant only for the periosteum (Fig. 1B). This resulted in a
significant increase in periosteal and endocortical BFR on both
surfaces in DMP1-caPTHR1 mice. Similar changes were found in
male and female mice.
We next examined the periosteal surface in the compact bone
of the skull, which is formed by intramembranous ossification
(Fig. 2). BFR measured on both the outer and inner calvarial
periosteal surface was also higher in the DMP1-caPTHR1 mice.
Calvarial thickness measured in transverse sections was 1.4-fold
higher in DMP1-caPTHR1 mice.
DMP1-caPTHR1 mice exhibit increased bone remodeling
in cortical bone
Previous histomorphometric analysis of cancellous bone at the
distal femur of DMP1-caPTHR1 indicated that not only osteoblast
but also osteoclast perimeter was elevated and quiescent surface
was decreased.(25) We also found abundant fluorochrome
incorporation, an index of intracortical (endosteal) bone
formation, in cortical bone at the femoral diaphysis (Fig. 1A)
as well as in calvaria (Fig. 2) of DMP1-caPTHR1 mice. In addition,
calvarial porosity measured histomorphometrically as percent
marrow area per bone area was observed only in calvariae of the
DMP1-caPTHR1 mice. In addition, abundant osteoclasts were
present only in DMP1-caPTHR1 calvaria. Taken together with the
previous findings that plasma and urine markers of bone
resorption are elevated in these mice,(25) these results indicate
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Fig. 1. Activation of PTHR1 signaling in osteocytes increases periosteal and endocortical bone formation. (A) Representative images of histologic sections
showing calcein and alizarin double labeling in femoral mid-diaphyses from 4.6-week-old DMP1-caPTHR1 mice andWT littermates. (B) Static and dynamic
histomorphometric measurements were performed in 3 male mice per group. Values are means SD. p< .05 versus WT mice.
Fig. 2. Activation of PTHR1 signaling in osteocytes increases periosteal bone formation in calvaria and induces intracortical remodeling. Representative
images of histologic sections showing calcein and alizarin double labeling in transverse sections taken 2mm anterior to the junction between the
frontoparietal and sagittal sutures (indicated by the red line) from 4.6-week-old WT and DMP1-caPTHR1 mice (top). TRAPase staining of calvarial sections
shows abundant osteoclasts in bones from DMP1-caPTHR1 mice (bottom). Bar indicates 50mm. Histomorphometric analysis was performed in the mid-
third of one frontal bone, excluding the area around the sutures. Periosteal BFR is the average of values of outer and inner periosteum. Calvarial marrow
space was calculated by measuring histomorphometrically the area occupied by marrow versus bone in the mid-third of one frontal bone. Values are
means SD; n¼ 3 male mice per group. p< .05 versus WT mice. ND¼not detected.
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that activation of PTH receptor signaling in osteocytes leads
to increased bone remodeling in cortical as well as cancellous
bone.
The periosteal bone phenotype of the DMP1-caPTHR1
mice is partially reversed in the absence of LRP5 and
abolished by Sost overexpression
Previous findings had shown that the increased cancellous bone
of the DMP1-caPTHR1 mice was reduced in mice also lacking the
Wnt coreceptor LRP5.(25) To examine whether a similar
mechanism was involved in the effect of the DMP1-caPTHR1
transgene on cortical bone, we analyzed the femoral mid-
diaphysis of the DMP1-caPTHR1 mice crossed with LRP5/
mice. As shown for younger mice in Fig. 1, 3-month-old DMP1-
caPTHR1 mice exhibited increased cross-sectional area, cortical
thickness, and cortical bone area (Fig. 3A, B). The increase in these
parameters was significantly reduced, but not eliminated, in
DMP1-caPTHR1 mice lacking LRP5. Similarly, the higher
periosteal BFR and mineralizing surface observed even in these
3-month-old DMP1-caPTHR1 mice was partially reversed in the
absence of LRP5. At this age, however, the effect of the DMP1-
caPTHR1 transgene on bone formation on the endocortical
surface did not reach significance.
The persistent effect of the DMP1-caPTHR1 transgene on
cortical bone in LRP5-deficient mice might result from remaining
increased Wnt signaling through LRP6. Sclerostin interacts with
and inhibits signaling through both LRP5 and LRP6.(30) To directly
address the role of suppressed Sost/sclerostin expression in the
actions of the caPTHR1, we generated mice overexpressing the
human Sost gene in osteocytes (DMP1-Sost mice) and crossed
them with DMP1-caPTHR1 mice. Expression of human Sost
mRNA was found only in DMP1-Sost mice, whereas endogenous
murine Sost was detected at similar levels in mice expressing or
not expressing the DMP1-Sost transgene (Fig. 4A). Mice
expressing the DMP1-caPTHR1 transgene exhibited decreased
expression of endogenous murine Sost, regardless of whether
the DMP1-Sost transgene was expressed. Immunohistochemistry
using an antibody against murine sclerostin that also recognizes
the human protein demonstrated sclerostin expression in osteo-
cytes in bone sections of WT and DMP1-Sost mice (Fig. 4B).
Consistent with previous findings,(25) sclerostin expression was
markedly decreased in osteocytes of DMP1-caPTHR1 mice. On
the other hand, DMP1-caPTHR1 mice co-expressing the DMP1-
Sost transgene exhibited persistent high expression of sclerostin
(Fig. 4B, upper panel). Although mRNA for the human Sost
transgene was expressed at lower levels in animals co-expressing
the DMP1-caPTHR1 transgene (Fig. 4A, left graph), human
sclerostin detected using an antibody specific for human protein
was present at apparent similar levels in DMP1-Sost mice and
DMP1-Sost;DMP1-caPTHR1 mice (Fig. 4B, lower panel).
BMD measurements taken at 4 weeks, 6 weeks (not shown),
and 8 weeks (Fig. 4C) of age revealed no significant change in
total or femoral BMD in DMP1-Sost mice. However, spinal BMD
was significantly lower at all ages (Fig. 4C and not shown). Micro-
CT analysis showed no changes in cortical bone area in the
femoral mid-diaphyses but a dramatic decrease in cancellous
bone volume in the vertebrae of DMP1-Sost mice (Fig. 4D).
Despite this apparent differential effect of the DMP1-Sost
transgene on cortical and cancellous bone, the increase in BMD
Fig. 3. Periosteal bone formation induced by PTH receptor signaling in osteocytes is reduced inmice lacking LRP5. (A) Representative images of histologic
sections show fluorochrome incorporation in femoral mid-diaphyses of 12-week-old WT and DMP1-caPTHR1 mice with or without LRP5. (B) Static and
dynamic histomorphometric measurements were determined in 3–4 male and female mice per group. Values are means SD. p< .05 versus respective
controls without the DMP1-caPTHR1 transgene; #p< .05 versus DMP1-caPTHR1 mice.
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exhibited by DMP1-caPTHR1 mice was completely abolished at
both the femur and spine in mice expressing both DMP1-
caPTHR1 and the DMP1-Sost transgenes (Fig. 4C, D). Further-
more, the double transgenic mice exhibited significantly lower
BMD in all sites than mice expressing solely the DMP1-Sost
transgene, because of increased osteoclast activity, as will be
discussed.
In contrast to the incomplete effect of deleting LRP5, the
higher cortical bone area exhibited by the DMP1-caPTHR1 mice
was completely eliminated in mice also expressing the DMP1-
Sost transgene (Fig. 5). Thus, total cross-sectional area, cortical
thickness, cortical bone area, and periosteal BFR in the double
transgenic mice were similar to those observed in DMP1-Sost
mice or in nontransgenic mice. Sost overexpression also
Fig. 4. The high bonemass phenotype of the DMP1-caPTHR1mice is abolished by overexpression of Sost in osteocytes. (A) Expression of human ormurine
Sost was detected in ulnae lysates by quantitative PCR; n¼ 3–5 female mice per group. ND, not detected. (B) Sclerostin expression was detected by
immunohistochemistry in tibiae using an antimurine sclerostin antibody that also recognizes human sclerostin or using a specific antihuman sclerostin
antibody. Bar indicates 10mm. (C) Total, femoral, and spinal BMD measured by DXA in 8-week-old mice expressing the DMP1-caPTHR1 and/or the DMP1-
Sost transgenes and in WT littermates is shown; n¼ 18–32 male and female mice per group. (D) Representative micro-CT images of cross-sections of
femoral mid-diaphyses (upper panel) and L3 (lower panel) of WT and DMP1-caPTHR1mice with or without the DMP1-Sost transgene. Cortical bone area as a
percentage of total area within the periosteal circumference (BA/TA) from the femoral diaphysis and trabecular BV/TV of the L3 bodyweremeasured in 4–7
male and female mice per group. Values represent the mean SD. p< .05 versus respective controls without the DMP1-caPTHR1 transgene; #p< .05
versus WT mice.
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reduced the increased thickness and periosteal bone formation
induced by the DMP1-caPTHR1 transgene in calvaria (Supple-
mental Fig. 2).
The elevated intracortical bone remodeling exhibited by
the DMP1-caPTHR1 mice is still present in the absence of
LRP5 and it is exacerbated by Sost over-expression
Despite the lower periosteal bone formation induced by the
DMP1-caPTHR1 transgene in LRP5/ mice or in mice over-
expressing Sost in osteocytes, DMP1-caPTHR1;LRP5/ and
DMP1-caPTHR1;DMP1-Sost mice displayed persistently higher
intracortical remodeling resembling that in DMP1-caPTHR1 mice
(Fig. 6). Thus, abundant intracortical fluorochrome incorporation
was still observed in sections of femoral mid-diaphysis and
calvaria (Figs. 3, S2, and 5). Calvarial marrow space was similarly
higher in DMP1-caPTHR1 mice lacking or expressing LRP5
(Fig. 6A), and double transgenic DMP1-caPTHR1;DMP1-Sost
mice exhibited even higher calvarial marrow space than mice
expressing only the DMP1-caPTHR1 transgene (Fig. 6B).
Osteoclast number per bone area quantified in von Kossa/
TRAPase calvarial sections displayed a similar profile (Fig. 6A, B).
Circulating levels of both formation (osteocalcin) and resorp-
tion (CTX) markers were increased in DMP1-caPTHR1 mice. CTX
was still elevated in DMP1-caPTHR1;DMP1-Sost mice (Fig. 6C).
However, osteocalcin levels in DMP1-caPTHR1;DMP1-Sost
mice were significantly lower than in DMP1-caPTHR1 mice, as
previously shown for DMP1-caPTHR1;LRP5/ mice.(25)
Interference with the Wnt pathway decreased the
expression of Wnt target genes and osteoblast markers
induced by PTH receptor activation in osteocytes, but
osteoclastogenic cytokines and osteoclast markers
remained increased
Long bones from DMP1-caPTHR1 mice exhibited increased
expression of Wnt target genes and of osteoblast and osteoclast
markers (Fig. 7). Gene expression was remarkably affected in
DMP1-caPTHR1 mice crossed with LRP5 null mice or with DMP1-
Sost mice. Thus, the higher expression of the recognized Wnt
target genes naked2, cyclin D1, Cx43, and BMP4(25,31) observed in
the DMP1-caPTHR1 mice was eliminated in mice also expressing
the Sost transgene (Fig. 7A). Naked2 expression was also
decreased toWT values by deletion of LRP5. However, expression
of cyclin D1 was barely affected, whereas Cx43 and BMP4
expression was reduced, although not eliminated, in DMP1-
caPTHR1;LRP5/ mice. Consistent with the higher periosteal
bone formation, the osteoblast markers alkaline phosphatase,
collagen 1a1, and osteocalcin were elevated in DMP1-caPTHR1
mice (Fig. 7B). Deletion of LPR5 did not affect alkaline
phosphatase expression, decreased collagen 1a1 expression
only partially, and completely blocked osteocalcin expression.
Sost overexpression abolished the increases in all these genes
exhibited by the DMP1-caPTHR1 mice.
In contrast, and consistent with the persistently increased
bone remodeling exhibited by DMP1-caPTHR1mice crossed with
LRP5/ or with DMP1-Sost mice, the osteoclast-specific genes
calcitonin receptor and TRAP remained elevated in DMP1-
caPTHR1;LRP5/ mice or in DMP1-caPTHR1;DMP1-Sost mice
Fig. 5. Periosteal bone formation induced by PTH receptor signaling in osteocytes is abolished by overexpression of Sost in osteocytes. (A) Representative
images of histologic sections show fluorochrome incorporation in femoral mid-diaphyses of 10.5-week-old WT and DMP1-caPTHR1 mice with or without
the DMP1-Sost transgene. (B) Static and dynamic histomorphometric measurements were determined in 3–5 mice per group. Values are means SD.
p< .05 versus WT mice.
PTHR1 SIGNALING IN OSTEOCYTES AND CORTICAL BONE Journal of Bone and Mineral Research 1041
(Fig. 7D). Expression of the osteoclastogenic cytokines M-CSF and
RANKL was increased in DMP1-caPTHR1 mice, and their levels
remained elevated, although not significantly for RANKL, in
DMP1-caPTHR1 mice crossed with LRP5/ or DMP1-Sost mice
(Fig. 7C). OPG expression, which was not different in DMP1-
caPTHR1 mice compared to WT littermates (Fig. 7C), was lower in
DMP1-caPTHR1;LRP5/ mice or in DMP1-caPTHR1;DMP1-Sost
mice. This resulted in a higher RANKL/OPG ratio in animals
expressing the DMP1-caPTHR transgene and lacking LRP5 or
overexpressing Sost.
Discussion
Early studies showing localization of radiolabeled PTH in
osteocytes and morphological changes in these cells upon
hormonal treatment had suggested the regulation of osteocyte
function by PTH.(32,33) The findings that PTH decreases the
expression of the osteocyte-derived inhibitor of bone formation
sclerostin suggested a mechanism by which the hormone could
increase bone mass through actions on osteocytes.(23,24) More
recently, we have shown that expression of a constitutively
active mutant of the PTH receptor in osteocytes is sufficient to
increase mass and remodeling in cancellous bone. (25) In the
present report, we found that DMP1-caPTHR1 mice exhibit
accelerated bone formation on the periosteal and endocortical
surfaces and increased intracortical remodeling, thereby show-
ing that PTH receptor signaling in osteocytes governs periosteal
bone formation and turnover also in cortical bone (Fig. 7E). These
actions of PTH receptor activation were observed in bones
formed by either endochondral or intramembranous ossification.
Moreover, higher periosteal apposition was found in both male
and female mice regardless of the age of the animals, showing
that the effect of PTH receptor activation in osteocytes overrides
Fig. 6. The increased bone resorption induced by PTH receptor signaling in osteocytes persists in the absence of LRP5 and is exacerbated by Sost
overexpression. (A,B) TRAPase/von Kossa staining of calvarial sections and histomorphometric quantification of calvarial marrow space, expressed as the
area occupied by marrow versus bone in the mid-third of one frontal bone, and of osteoclasts, expressed as number per bone area. n¼ 4 mice/group. Bar
indicates 50mm. (C) Osteocalcin and CTX were measured in plasma of 10.5-week-old DMP1-caPTHR1 mice, with and without the DMP1-Sost transgene.
Bars represent the mean SD; n¼ 7–23 mice per group. p< .05 versus WT and LRP5/ or DMP1-Sost mice, respectively; #p< .05 versus DMP1-caPTHR1
mice.
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the recognized action of growth as well as androgens on
periosteal bone formation and size of long bones.(34)
The current findings also show that the anabolic effect of PTH
receptor signaling on the periosteal surface of cortical bone is
dependent on inhibition of sclerostin expression, as the effect of
the caPTHR1 transgene was abolished by overexpressing Sost in
osteocytes. However, as judged by the persistent fluorochrome
incorporation, bone formation coupled to the intracortical
resorption exhibited by the DMP1-caPTHR1 mice was not
decreased by removing LRP5 or overexpressing Sost. These
findings suggest that sclerostin differentially regulates model-
ing-based periosteal bone formation versus remodeling-based
endosteal bone formation. Further studies are warranted to
specifically address the role of resorption on bone formation
induced by PTH receptor signaling in osteocytes.
Expression of the endogenous (murine) Sost gene was lower in
DMP1-caPTHR1 mice, regardless of whether the DMP1- (human)
Sost transgene was co-expressed. This is consistent with earlier
Fig. 7. The increased expression of Wnt target genes and osteoblast markers induced by PTH receptor activation in osteocytes was obliterated by
interfering with the Wnt pathway, but osteoclast markers were still elevated and OPG was markedly reduced. (A–D) Gene expression was measured by
quantitative PCR. Results are expressed relative to the housekeeping gene ribosomal protein S2. Bars represent mean SD of 4–5mice per group. p< .05
versus respective controls without the DMP1-caPTHR1 transgene. (E) Schematic representation of the effects on cortical bone of PTH receptor signaling in
osteocytes. Constitutive activation of PTH receptor in osteocytes (DMP1-caPTHR1mice) leads to cAMP-dependent Sost downregulation and increasedWnt
signaling, which in turn stimulates periosteal bone formation. PTH receptor activation in osteocytes also increases RANKL expression and intracortical
remodeling. However, OPG expression is not affected, likely resulting from opposing effects on the expression of the gene by cAMP (reduction) and Wnts
(elevation). When PTH receptor activation is combined with reducedWnt signaling (LRP5 deficiency or Sost overexpression), the cAMP-mediated decrease
in OPG prevails, leading to a markedly increased RANKL/OPG ratio and exacerbated bone resorption in the cortex.
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findings that PTH downregulates the expression of Sost/
sclerostin in vivo and in vitro(23,24) and with our previous
report.(25) Keller and colleagues showed that inhibition of Sost
expression by PTH is exerted through modulation of the
transcription factor Mef2c through binding on the same distant
regulatory region of the Sost gene promoter that confers bone-
specific expression of the gene.(35) Expression of the human Sost
transgene in our DMP1-Sost mice is directed by the DMP1
promoter, not by the regulatory regions of the Sost gene.
Therefore, the lower levels of human Sost mRNA observed in
animals expressing both the DMP1-Sost and the DMP1-caPTHR1
transgenes might result not from direct gene regulation by PTHR
activation but rather from changes either in osteocyte number or
in their state of maturation. Nevertheless, even when human Sost
mRNA expression was lower, human sclerostin protein was still
detected at high levels in the double transgenic mice.
The mechanism by which sclerostin, the product of the Sost
gene secreted by osteocytes, inhibits bone formation is not
completely understood. However, the current knowledge
indicates that sclerostin binds with high affinity to LRP6 and
LRP5, transmembrane proteins that together with frizzled
receptors mediate the actions of Wnt ligands. It is believed
that sclerostin binding interferes with signaling downstream of
these receptors, thereby antagonizing the pro-differentiating
and survival actions of Wnts on cells of the osteoblastic
lineage.(36,37) It was recently shown that sclerostin also associates
with LRP4, another member of the LRP family of proteins,(38,39)
although its role in Wnt signaling is still uncertain. Nevertheless,
it is possible that the remaining phenotypic features of PTH
receptor activation in the absence of LRP5 observed in the
current study in cortical bone, as well as in cancellous bone in our
previous study,(25) result from Wnt signaling through alternative
LRPs.
Because the increase in bone mass exhibited by DMP1-
caPTHR1 mice is reduced in mice lacking LRP5, and because a
recent report indicated that LRP5 increases bone formation by
inhibiting serotonin synthesis in the duodenum,(40) we examined
whether the high bone mass of the DMP1-caPTHR1 mice was
associated with decreased intestinal expression of Tph1, the
enzyme that controls serotonin synthesis. We found no
significant changes in Tph1 expression in the duodenum, colon,
or bone of DMP1-caPTHR1 compared to its expression in WT
littermates (Supplemental Fig. 1). Moreover, DMP1-Sost mice did
not exhibit higher levels of Tph1 expression in either the
intestine or bone, as would be expected if the low bone mass in
these mice was due to increased serotonin (Supplemental Fig. 1).
Consistent with our findings, Robling, Warman, and colleagues
have not detected changes in Tph1 in the intestine of the low-
bone-mass LRP5/ mouse or in the high-bone-mass LRP5
G171V knock-in mouse.(41) Taken together, these findings are
inconsistent with the involvement of gut-derived serotonin in
the bone formation changes exhibited by DMP1-caPTHR1 mice
with or without LRP5 deletion or Sost overexpression, and they
support the role of osteocyte-mediated regulation of the Wnt
pathway on bone mass.
The higher periosteal BFR and cortical thickness exhibited by
the DMP1-caPTHR1 mice contrast with the decreased periosteal
BFR and thinner cortices found in mice in which the same active
PTH receptor mutant is expressed under the control of the 2.3
fragment of the collagen 1a1 gene promoter (Col1a1-caPTHR1
mice), which is active not only in osteocytes but also in
preosteoblasts and mature osteoblasts.(42) Direct comparison of
micro-CT images of calvarial bones of 4-week-old mice
confirmed that Col1a1-caPTHR1 mice exhibit decreased calvarial
thickness, whereas DMP1-caPTHR1 mice exhibit increased
calvarial thickness compared to WT mice of the same age
(Supplemental Fig. 3). The divergent outcomes of activating the
PTH receptor in different types of osteoblastic cells suggest that
the positive effect on cortical bone formation induced by PTH
signaling in osteocytes is counterbalanced by simultaneous
activation of PTH signaling in osteoblast precursors or mature
osteoblasts. This antagonistic effect might result from direct
inhibition of periosteal osteoblast differentiation by PTH receptor
activation, and it is consistent with the accumulation of
immature osteoblasts with chronic elevation of PTH, such as
in severe hyperparathyroidism(43) or in the Col1a1-caPTHR1
transgenic mice.(42,44) This phenomenon might also help explain
the failure of PTH to increase bone formation in the periosteal
surface in some conditions.(17–19)
The osteopenic phenotype of the DMP1-Sost transgenic
mouse observed in vertebral cancellous bone is consistent with
previous reports describing mice overexpressing human Sost
under the control of the murine osteocalcin (OG-2) promoter(45)
or under the control of the regulatory regions of the Sost gene.(46)
However, cortical bone volume in the femoral mid-diaphysis was
not decreased in our DMP1-Sost mice up to 2months of age. This
is in agreement with the milder decrease in femoral BMD
compared to lumbar vertebra observed in OG2-Sost mice by
Winkler et al.(45) Future studies will be required to determine
whether the phenotype of our DMP1-Sost animals becomes
more prominent with age in both the axial and appendicular
skeleton, as observed in 5-month-old human Sost mice in the
study by Loots et al.(46)
In spite of the different effect of the Sost transgene by itself on
cancellous versus cortical bone, Sost overexpression equally
abolished the increase in bone mass and volume induced by the
DMP1-caPTHR1 transgene in both bone envelopes. These
findings confirm that the anabolic effect of PTH receptor
signaling in osteocytes requires Sost/sclerostin downregulation.
Sost overexpression converted the bone gain exhibited by the
DMP1-caPTHR1 mice into a bone loss in the DMP1-
caPTHR1;DMP1-Sost mice. Thus, the double transgenic mice
exhibit reduced total, femoral, or spinal BMD compared to
animals expressing only the DMP1-Sost transgene and a
persistent increase in osteoclasts in the face of absent Wnt
signaling and reduced expression of Wnt target genes and
osteoblast markers. Similar effects were observed in DMP1-
caPTHR1 mice lacking LRP5. OPG expression was not different in
DMP1-caPTHR1 mice compared to WT littermates, likely because
of opposing effects of PTH receptor signaling on the OPG gene.
Indeed, PTH inhibits OPG transcription by activating the cAMP-
response element-binding protein (CREB),(47) and Wnt signaling
stimulates OPG transcription(48,49) (Fig. 7E, left panel). Consistent
with this, OPG expression was markedly decreased OPG
expression was markedly decreased in DMP1-caPTHR1 mice
lacking LRP5/ or overexpressing Sost, showing that when Wnt
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signaling is reduced, the cAMP-dependent inhibition of OPG
expression prevails (Fig. 7E, right panel), resulting in a higher
RANKL/OPG ratio. This is particularly noticeable in the double
transgenic DMP1-caPTHR1;DMP1-Sost mice in which resorption
is exacerbated, as evidenced by higher osteoclast number and
calvarial marrow space compared to mice expressing only the
caPTHR1 transgene. These observations, together with recent
evidence showing that deletion of b catenin-dependent
canonical Wnt signaling in osteocytes leads to reduced levels
of OPG and increased resorption,(50) support a crucial role for
osteocyte-derived OPG in bone resorption.
In closing, our study shows that activation of PTH receptor
signaling in osteocytes dictates the recognized actions of PTH on
formation and resorption in cortical bone and defines the role of
the Wnt pathway. Acceleration of periosteal bone formation and
apposition is due to downregulation of sclerostin, whereas the
increase in osteoclast activity and intracortical remodeling is
driven by osteocyte-dependent regulation of osteoclastogenic
cytokines. Whether the mechanisms identified herein operate
under conditions of endogenous elevation of PTH and/or
administration of the hormone will require models of osteocyte-
specific deletion of the PTH receptor. Our findings reveal that
osteocytes are critical players in the regulation of cortical bone
biology, opening new avenues to fracture prevention by
targeting these most abundant bone cells.
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